aTyr Pharma, Inc.(US:ATYR)2025-07-03 13:07Efzofitimod for Interstitial Lung Disease (ILD) - Efzofitimod is a first-in-class biologic immunomodulator in Phase 3 development for ILD, addressing a significant unmet medical need[10] - aTyr is advancing Efzofitimod as the standard-of-care for ILD, which encompasses over 200 types of rare lung diseases[11, 13] - The company's current focus is estimated at a $2-5 billion global market opportunity[13] - Efzofitimod is positioned to be the first approved product for sarcoidosis in over 60 years[31] Clinical Development and Trial Design - Phase 3 catalyst for multi-billion dollar indication in Q3 2025[6] - The Phase 3 EFZO-FIT study in pulmonary sarcoidosis is fully enrolled with 268 patients, and topline data is expected in Q3 2025[50] - Interim data from the Phase 2 EFZO-CONNECT study in SSc-ILD is expected in Q2 2025[70] - The addressable population for Efzofitimod in sarcoidosis is estimated to be 50-75% of all sarcoidosis patients[28] Financial Position and Pipeline - The company had approximately $68.9 million in cash, restricted cash, cash equivalents, and investments as of Q3 2024, with an additional $19.4 million raised subsequently[70] - The company's cash runway extends through the filing of a Biologics License Agreement (BLA) for efzofitimod in pulmonary sarcoidosis[70]